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Abstract
Background: Thrombolysis is a dynamic and time-dependent process influenced by the haemodynamic
conditions. Currently there is no model that allows for time-continuous, non-contact measurements under
physiological flow conditions. The aim of this work was to introduce such a model.
Methods: The model is based on a computer-controlled pump providing variable constant or pulsatile flows in a
tube system filled with blood substitute. Clots can be fixed in a custom-built clot carrier within the tube system.
The pressure decline at the clot carrier is measured as a novel way to measure lysis of the clot. With different
experiments the hydrodynamic properties and reliability of the model were analyzed. Finally, the lysis rate of clots
generated from human platelet rich plasma (PRP) was measured during a one hour combined application of
diagnostic ultrasound (2 MHz, 0.179 W/cm
2) and a thrombolytic agent (rt-PA) as it is commonly used for clinical
sonothrombolysis treatments.
Results: All hydrodynamic parameters can be adjusted and measured with high accuracy. First experiments with
sonothrombolysis demonstrated the feasibility of the model despite low lysis rates.
Conclusions: The model allows to adjust accurately all hydrodynamic parameters affecting thrombolysis under
physiological flow conditions and for non-contact, time-continuous measurements. Low lysis rates of first
sonothrombolysis experiments are primarily attributable to the high stability of the used PRP-clots.
Background
In ischemic stroke therapy, a critical need exists for early
treatment to prevent neuronal loss. Several trials have
shown that thrombolytic therapy in cerebral ischemia can
reduce stroke disability in selected patients. In addition,
the increased use of thrombolytic therapy has revealed sig-
nificant limitations and stimulated efforts to improve
effectiveness and decrease bleeding complications.
The use of ultrasound to enhance thrombolytic ther-
apy (called sonothrombolysis) represents a complemen-
tary approach with unique features, as its effects are
limited to the insonified area. Therefore, thrombolytic
activity can be enhanced at the site of the vessel
occlusion without increasing the risk of systemic bleed-
ing complications. Although the supporting effect of
ultrasound for thrombolysis is proven [1-4] and an
enhanced lysis rate by a combined exposure to ultra-
sound and thrombolytics [5-7] or gas-filled microbub-
bles has been demonstrated [8,9], the underlying
mechanisms are still unknown and require further inves-
tigations. In-vitro models are most suitable for such
basic research, because they are safe, facilitate fast and
accurate adjustments of experimental parameters, are
inexpensive compared to animal or clinical studies, and
provide reproducible results.
Most in-vitro models study the effect of thrombolytics
or ultrasound on a clot stored in a resting fluid by mea-
suring its weight loss [6,7,10-13] or the wash-out of
radioactivity when radiolabel l e dc l o t sa r eu s e d[ 1 4 , 1 5 ] .
Other experimental setups provide clots within fluids
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measured here by collecting the perfusion fluid per min-
u t e[ 1 6 ] ,b yu s i n gp h o t o e l e c t r i ct e c h n i q u e s[ 1 9 ] ,o rb y
detecting flow velocities [18]. Clot dissolution is mea-
sured by weighing [4,17] or detecting concentrations of
radiolabelled clot components [18]. A few investigators
have applied roller pumps to generate pulsatile but
unphysiological flow [20]. It has been frequently pointed
out, however, that physiological flow and pressure have
to be considered in experiments for thrombolysis,
because the mechanical stress of streaming fluids affects
clot lysis [21-25]. Knowledge about the interaction of
thrombolysis and haemodynamic parameters such as
blood pressure might lead to far-reaching consequences
for clinical treatment [25-27].
Only a few models allow temporally resolved measure-
ments [18,19]. Time-continuous measurements of the
temporal dynamic of thrombolysis, however, are essen-
tial in defining a lysis strategy that is both effective and
safe. In most models, the clot has to be removed from
the experimental setup to determine the lysis rate when
using a method such as weighing. Methods like this
interfere with the process of thrombolysis and might
lead to inaccuracies.
In sight of these considerations the aim of this work
was (1) to introduce a new in-vitro pulsatile flow model
that meets these conditions, (2) to prove its reliability
and describe its characteristics, and (3) to demonstrate
its feasibility by first experiments.
Methods
The experimental setup is shown in Figure 1. A compu-
ter-controlled pump generates pulsatile flow velocities at
defined values. A blood substitute (Ringer solution, Ber-
lin-Chemie Menarini, Berlin, Germany), stored in a
reservoir at a controlled temperature of 37°C and a pH
of 7.4, circulates through a tube system (sheathed PVC,
6 mm inner diameter). Varying the computer-controlled
flow velocity and the resistance of the tube system using
a modulating valve (Teflon
® 1/8’’ FNPT: Aalborg, Oran-
geburg NY, USA) leads to a defined adjustment of pres-
sure and flow velocity at the same time. A clot is placed
within a custom-built carrier, permitting accessibility for
thrombolytics and ultrasound. The part of tube system
containing the clot carrier runs through a basin filled
with degassed water. Ultrasound is applied through a
flexible silicone foil and enters the inside of the clot car-
rier through an acoustic window. Acoustic absorbers
prevent ultrasonic reflections. Thrombolytics are applied
at continuous rates via small tubes into the interior of
the clot carrier (see also Figure 2). One flow velocity
sensor before and two pressure sensors located 0.07 m
before and behind the clot carrier are used to record
data online. Because of its special shape, the pressure
decline at the clot carrier is monotonically related to the
hydrodynamic resistance of the clot and, therefore, to its
size. We aim to detect reductions in this pressure
decline as a new means of measuring the lysis rate of
the clot.
Figure 1 Model setup. Detailed explanations are given in the text. m.v. = modulating valve. Solid arrows: Direction of the streaming blood
substitute. Dashed arrows: Options to modify hydrodynamic conditions. Dotted arrows: Acquisition of data.
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A progressing cavity pump (2-E15A: Netzsch, Selb, Ger-
many) was used. With a custom-built program (Lab-
VIEW) controlling the pump, any given pulsatile or
constant flow velocity can be achieved within a range of
0 to 0.95 m/s. The pulsatile flow used in the experi-
ments reflects common physiological flow velocity
curves found in the internal carotid artery of healthy
subjects recorded by duplex measurements (Figure 3).
Clot carrier
Figure 2 shows the design of the custom-built clot car-
rier. During the experiments, the carrier is located inside
the tube system filled with the blood substitute. The
carrier is composed of a cylindrical pipe made of poly-
oxymethylene (POM) with a concentrical cavity where
the clot is placed during the experiments.
The cavity is closed at the distal end by gauze. A gap
at one side of the pipe allows the application of ultra-
sound with a minimized loss of energy. Using small
tubes, human plasma and thrombolytics can be applied
directly into the cavity of the pipe where the clot is
located. Perfusor syringes (Pilot A2, Fresenius SE, Bad
Homburg, Germany) ensure a uniform and defined
application of plasma and thrombolytic agent. Thus the
clot is ensheathed by a mixture of plasma and thrombo-
lytic agent despite the circulating blood substitute. To
minimize the hydrodynamic resistance of the carrier,
long channels allow the circulating fluid to pass by even
if the cavity of the pipe is completely filled with a clot.
Channels connected with the cavity by small holes drain
more fluid when the clot becomes smaller and the
blocked holes open. During clot lysis, the increased flow
rate streaming through the cavity-connected-channels
leads to a decreased pressure decline measured at the
clot carrier.
Clot preparation
Human venous blood is obtained from different donors
of the same blood group who are not taking anticoagu-
lants or antithrombotic medications. Blood sampling has
been approved by the ethics committee of the University
of Lübeck and is conducted by the local Department of
Transfusion Medicine, within the clinical routine. Blood
is drawn into citrate tubes (S-Monovette
®:R E F
02.1067.001, Sarstedt, Nümbrecht, Germany) and pooled
to avoid individual differences concerning the blood
consistency and its quality of clotting. After centrifuga-
tion at 180g for 10 minutes (Multifuge
® 1S-R: Heraeus
Holding GmbH, Hanau, Germany) 3.5 ml of platelet
rich plasma (PRP) are removed by aspiration of the
supernatant and mixed with 0.5 ml of the boundary
layer, which formed between the supernatant and the
erythrocyte layer. Clot formation is achieved by recalcifi-
cation (final concentration of CaCl2: 13.8 mmol/l) and
incubation at 37°C for 2 hours.
Figure 2 Custom-built clot carrier. Detailed explanations are
given in the text. (1) tube system, (2) direction of streaming blood
substitute, (3) cavity for the clot, (4) gauze, (5) gap for ultrasound
application, (6) tubes for thrombolytic supply, (7) channels reducing
the hydrodynamic resistance of the carrier, (8) channels connected
with the clot cavity by small holes (9) providing an decreased
hydrodynamic resistance when the clot is getting smaller. White
arrows A - D: Successively increased flow rate during clot
dissolution.
Figure 3 Creation of physiological flow velocity profiles.T h e
envelope-data of flow velocity profiles obtained by duplex
measurements in normal internal carotid arteries of healthy subjects
are supplied to a custom-built computer program controlling a
progressing cavity pump that excites a replication of the measured
flows in the tube model. Thereby and by adjusting the modulating
valve, for the first lysis experiments flow velocity curves and pulse
pressure waves of a fictitious patient suffering from hypertension
were generated. MP = mean pressure.
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A custom-built ultrasonic flow meter (developed by the
Fraunhofer Institute for Biomedical Engineering IBMT,
St. Ingbert, Germany) is used to measure flow velocity
based on correlation methods. Two ultrasound transdu-
cers are placed directly opposite from each other and
aligned parallel to the direction of the streaming fluid
(Figure 1). The transducers work alternately as emitter
or receiver. Thus, ultrasound can be emitted and
received in both directions. In flow direction, the time
of flight of the ultrasound (t+) is shorter than in the
reverse direction (t-). Flow velocity is calculated by mea-
s u r i n gt h et i m eo ff l i g h td i f f e r e n c eo ft h et w oe m i t t i n g
directions with a sampling rate of 1 Hz:
V˜ (t− − t+)(t− + t+)
−2 (1)
Pressure measurement
Pressure sensors (REF I-99-IA-013, pvb
®: Critical Care
GmbH, Kirchseeon, Germany) are connected to the
tube system before (P1) and behind (P2) the clot carrier
for a continuous recording of the pressure decline at the
clot carrier (ΔP = P1-P2).
Experimental analysis of the reliability of the model
According to Ohm’s law the pressure decline that is
measured to monitor thrombolysis depends not only on
t h ec l o tv o l u m eb u ta l s oo nt h ef l o wv e l o c i t yo ft h e
streaming blood substitute. Therefore a defined control
of the flow velocity is necessary for all experiments with
streaming fluids. The model was validated with three
different measurements:
1) The accuracy of the flow meter was tested by volu-
metric measurements. 10 different constant flow veloci-
ties were excited by the pump and measured by the
flow meter continuously for 5 minutes. The mean of the
recorded data was compared with the flow velocity cal-
culated from the collected fluid volume and the cross
sectional area of the tube system.
2) The temporal stability of flow velocities excited by
the pump was verified by continuous four-hour flow
measurements using the ultrasonic flow meter. Two
flow velocities were adjusted at the pump, that coincide
with the minimum and maximum values of the pulsatile
flow velocity used in the subsequent lysis experiments
(0.29 and 0.64 m/s). To ensure stable testing conditions
the clot carrier was totally filled with non-deformable
POM.
3) Furthermore the dependence of flow velocity on the
hydrodynamic resistance was analyzed. The pump was
set to 5 different flow velocities within the available
range of 0 to 0.95 m/s. Flow velocity was recorded for 1
minute in front of the gradually POM-charged clot car-
rier (0 - 100%) and averaged.
4) Finally the attenuation of ultrasound on its way to
the cavity of the clot carrier was determined to test
whether it coincides with values found in the literature
for the attenuation of diagnostic ultrasound transcra-
nially applied to the M1 segment of the middle cerebral
artery of human beings. Ultrasound was supplied by a
SONOS 2500 (Hewlett Packard, Palo Alto, California,
USA) driven in the transcranial colour-coded ultrasound
mode (2 MHz, 0.179 W/cm
2)a si ti sc o m m o n l yu s e d
for diagnostic purposes. A custom-built hydrophone
(developed by the Fraunhofer Institute for Biomedical
Engineering IBMT, St. Ingbert, Germany) with a centre
frequency of 2 MHz and a bandwidth of 100% (1 MHz -
3 MHz) was inserted into the centre of the cavity of the
clot carrier. According to the experimental setup
depicted in Figure 1 the clot carrier was located within
the tube system that runs through the basin filled with
degassed water. The distance between the hydrophone
and the ultrasound transducer was 50 millimetre. Inside
t h ec l o tc a r r i e rt h eu l t r a s o u n di n t e n s i t yI 1 was deter-
mined by the hydrophone and read off an oscilloscope
(HP 54520A, Hewlett Packard, Palo Alto, California,
USA). For reference measurements the ultrasound
intensity I0 was determined when ultrasound was
applied from the water surface of the basin to the
unshielded hydrophone mounted at the same distance
of 50 mm within the degassed water. Attenuation A was
determined five times by:
A=1 0 l o g ( I 0 /I 1) (2)
Experimental analysis of the hydrodynamic properties of
the custom-built clot carrier
To describe the hydrodynamic properties of the custom-
built clot carrier its resistance was calculated by Ohm’s
law on the basis of pressure declines at the clot carrier
at different filling levels and flow velocities of the
streaming blood substitute. For each flow velocity and
each filling level three independent measurements of the
pressure decline were performed. For each measurement
the clot carrier was completely disassembled into its
component parts and afterwards recomposed. Again,
POM was used for the fillings.
First non-contact and time-continuous measurements of
in-vitro thrombolysis
To prove the feasibility of the model the pressure
decline at the clot-filled carrier was time-continuously
measured for clots solely undergoing a defined pulsatile
flow (group A). Flow and pressure were adjusted before
the clot carrier was filled to simulate the hydrodynamic
situation within the internal carotid artery of a patient
with hypertension (Figure 3). Systolic and diastolic flow
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leading to a mean pressure (MP) of 130 mmHg.
In a second experimental group B the pressure decline
was determined for clots under the same flow condi-
tions and the influence of a typical scenario of sono-
thrombolysis using diagnostic ultrasound and rt-PA
(Actilyse
®, Boehringer Ingelheim Pharma GmbH & Co.
KG, Ingelheim, Germany) as thrombolytic drug. Starting
at t = 60 minutes diagnostic ultrasound as described
above was continuously applied for 1 hour. The distance
between the clot within the clot carrier and the ultra-
sound transducer was 50 millimetres corresponding to
the distance between the M1 segment of the human
middle cerebral artery and the acoustic window of the
human temporal bone. During ultrasound application 80
ml of a mixture of rt-PA and human blood plasma (final
concentration of rt-PA: 60 kU/ml) were continuously
injected into the clot carrier. Incubation time for clots
of group B was reduced to 1 hour. In both groups A
and B the same pulsatile flow was used. For each group
5 experiments with a clot-filled carrier were performed.
A slight shifting of the pres s u r ed e c l i n ei se x p e c t e d
caused by small fluctuations of the flow velocity and
temperature of the model. To evaluate this biased error
5 additional measurements with the carrier filled with
non-deformable POM were made for each group A and
B under the same experimental setups as they were
used for the experiments with the clots. These addi-
tional measurements serve as control groups. In each
experiment, the pressure decline at the clot carrier was
continuously measured over a period of 4 hours, using a
sampling rate of 10 Hz. Data were processed as follows:
 PE
F,i(t,V)(i = 1, ..., n) is defined to be the pressure
decline measured in one of n = 5 experiments of group
E = A or B with the carrier filled by a clot (F = CLOT)
or POM (F = POM). The biased error D
E(t,V) is deter-
mined for each group E by
DE(t,V) =  P
E
POM(t,V) −  P
E













POM(t,V) is the mean pressure decline of each con-
trol group. The biased error is subtracted from each
time course measured with a clot under the appropriate
experimental condition. For each group A and B this




CLOT,i(t,V) =  PE
CLOT,i(t,V) - D
E(t,V) with i = 1,..., 5 and E = A,B. (4)
To allow for a direct comparison between all experi-
ments the “normalized pressure decline” ZE
CLOT,i(t) was







with i = 1, ...,5a n dE=A ,B . (5)
At the start of each measurement (t = 0) the value of
the normalized pressure decline is 1. When the hydro-
dynamic resistance of the clot decreases during the mea-
surement the values of ZE
CLOT,i(t) are less than 1 and
tend to a small positive value near zero when the clot
dissolves completely. The following data of ZE
CLOT,i(t) are
reported as mean ± standard error of mean.
Results
Reliability of the model
1) Measuring flow velocity by flow meter lead to mar-
ginally lower values compared with results of the volu-
metric measurement. Within the measuring range of 0
to 0.95 m/s the relative error never exceeded 0.04% (Fig-
ure 4).
2) A slight decrease was found for constantly adjusted
flow velocities in the course of a four-hour measurement.
Its maximum value accounted for 2.34% (Figure 5).
3) Flow velocities generated by the pump varied spar-
sely with changed hydrodynamic resistance. Within the
available flow velocity range of 0 to 0.95 m/s no filling
Figure 4 Accuracy of flow velocity measurement. Figure above:
Comparison between the flow velocities measured by the flow
meter (VF) and by volumetric measurements (VV). Figure below:
Absolute error of flow velocity measurements performed by the
flow meter.
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0.81% (Figure 6).
4) For the attenuation of diagnostic 2 MHz-ultrasound
(0.179 W/cm
2) a value of 7.3 dB ± 0.7 dB was found for
the described experimental setup.
Hydrodynamic properties of the custom-built clot carrier
At low filling levels the resistance of the clot carrier was
constant and independent of the flow velocity of the
streaming blood substitute. With increasing filling levels
the hydrodynamic resistance of the clot carrier increased
exponentially and was correlated by a power law with
increasing flow velocities. Repeated measurements
showed reproducible results (Figure 7).
First measurements of in-vitro thrombolysis
In a four-hour period, no significant difference in
thrombolysis between the conditions A and B (Figure 8)
was detected. Clots prepared from platelet rich plasma
with an incubation time of 2 hours showed only a negli-
gible dissolution under the adjusted pulsatile flow
(group A). During the first minutes the normalized pres-
sure decline of group A temporarily increased and stabi-
lized finally at a mean value of about 0.98. Dissolution
increased non-significantlyi ng r o u pB .C o m p a r i n gt o
group A, clots prepared from platelet rich plasma with
an incubation time of only 1 hour dissolved a little bit
more during the first hour of the experiment reaching
an intermediate value just below 0.96. After treatment
with ultrasound and rt-PA the normalized pressure
decline further decreased and stabilized at a mean value
of about 0.91.
Discussion
We created an in-vitro pulsatile flow model for the
investigation of thrombolysis. In contrast to all pre-
viously used experimental setups, the model generates
defined physiological or pathological flow conditions.
The model allows for time-continuous and non-contact
measurements based on the recording of pressure gradi-
ents. Compared with other methods of measurement
(e.g. magnetic resonance imaging [21], chemical analysis
or radiolabeling [14,15,18]), this technique is very
inexpensive.
In various experiments the model proved its opera-
tional reliability. Flow velocities can be adjusted accu-
rately, remain sufficiently stable for long experimental
periods and are nearly independent of the filling levels
of the clot carrier. For each measurement of the calibra-
tion curve (Figure 7) the experimental setup was com-
pletely reassembled to assure totally independent
experiments. The collected data prove high reproducibil-
ity of the method.
Investigations of the hydrodynamic behaviour of the
clot carrier show that clot dissolution can be observed
with highest resolution at high filling levels where the
highest gradients of the hydrodynamic resistance of the
clot carrier are found (Figure 7). Therefore, the model is
most suitable for the discrimination of small lysis rates.
With increasing filling levels and flow velocities there is
an increased eddying flow leading to a non-linear hydro-
dynamic resistance of the clot carrier. This hydrodynamic
behaviour reflects in-vivo turbulences in the region of
vessel stenosis and requires an accurate mathematical
analysis of the recorded data. For comparing lysis rates
achieved under different flow conditions a diagram with
rating curves as depicted in Figure 9 is needed.
First experiments concerning the lysis rates of clots
prepared from platelet rich plasma reveal only small
effects. For group A the hydrodynamic resistance of the
clots temporarily increases, probably because the clots
are pressed into the carrier by the streaming fluid and a
mechanically induced deformation might lead to a tigh-
ter occlusion. Although this effect might also occur in
group B, the normalized pressure decline decreases,
Figure 5 Temporal stability of flow velocities. The highest and
lowest flow velocity value used in the experiments were adjusted
and measured continuously by the flow meter for 4 hours (VF).
Figure 6 Stability of flow velocities in dependence of the
hydrodynamic resistance. After adjusting different flow velocities
at the pump their values were measured with the flow meter (VF)
for increasing filling levels (L), respectively hydrodynamic resistances,
of the clot carrier.
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to a lower strength of the less compact clots and an
increased attrition at their surfaces. This might also be
the reason for the further drop of the normalized pres-
sure decline in group B during the first hour of the
experiment. The data do not permit a decision whether
the second drop of the normalized pressure decline in
group B, starting after approximately 100 minutes, is
attributable to those mechanical forces or the impact of
sonothrombolysis. Therefore higher lysis rates have to
be achieved, which would enable the discrimination
between experiments with or without the application of
sonothrombolysis. The small lysis rates found in the
reported experiments are presumably caused by the fol-
lowing reasons:
1. Thrombolysis is mainly affected by the composition
of the used clots [24]. The platelet rich clots of the cur-
rent experiments are of a very firm and robust consis-
tence with a relative clot mass loss of about 17% after a
2-hour incubation at 37°C in a solution of buffered
plasma with pH = 7.4 and rt-PA (final concentration: 60
kU/ml) [28]. According to Mizushige et al. [29] who
reported on low lysis rates for artificial white thrombi,
this is low compared to the mass loss of about 64% we
found under the same treatment for clots generated by
spontaneously clotted whole venous blood [28]. Such
clots are used by many other research groups for experi-
ments with static or non-physiological flow conditions
[4,11]. On the other hand, spontaneously clotted whole
venous blood is unsuited for experiments under physio-
logical flow conditions because it completely dissolves
within seconds under the influence of the streaming
fluid [28]. This work was not focused to investigate the
clotting process in detail but the results point out that
for future experiments clots are needed that resist pulsa-
tile flows on the one hand, and show sufficient lysis
rates on the other hand. In our opinion, the low lysis
rates of the first experiments with platelet rich clots
reflect those clinical situations, in which delayed, incom-
plete, or even no lysis are observed [30].
2) It might be possible, that the used amount of rt-PA
and plasma is too small for a sufficient thrombolysis.
Therefore dose-finding experiments are planned.
3) Finally attenuation of the applied ultrasound might
be too high. Measurements revealed a value of about 7.3
dB for the used diagnostic 2 MHz-ultrasound (0.179 W/
cm
2)i nt h ed e s c r i b e de x p e r i m e n t a ls e t u p .A a s l i de ta l .
report on a value of 7.0 dB for a 2 MHz-ultrasound pas-
sing through the human skull [31]. Pfaffenberger et al.
determined ultrasound attenuations between 8.8 and
Figure 7 Calibration curves describing the hydrodynamic behaviour of the clot carrier. The hydrodynamic resistance of the clot carrier (R)
is shown as a function of the flow velocity of the streaming blood substitute (V) and the filling level of the clot carrier (L). For each
measurement the experimental setup was completely reassembled to assure totally independent experiments.
Figure 8 Normalized pressure decline at the clot-filled carrier
for two different thrombolysis experiments (each n = 5). Group
A (black curves): Clots with an incubation time of 2 hours under a
defined pulsatile flow condition. Group B (red curves): Clots with an
incubation time of 1 hour under the same pulsatile flow condition
undergoing sonothrombolysis (combined treatment with ultrasound
and the thrombolytic agent rt-PA) between t = 60 and 120 minutes.
Solid lines: Starting point normalized, error adjusted mean values.
Dashed lines: Standard errors.
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and a diagnostic ultrasound device (Sonos 4500, Philips,
Hamburg, Germany) with a mean frequency of 1.8 MHz
[10]. Although these data imply that attenuation mea-
sured in the experimental setup has the appropriate
physiological dimension, it has to be considered that
measurements carried out with different ultrasound
devices can not be compared directly.
Despite low lysis rates the essential advantage of the
presented model is clearly evident: Unlike all previously
used models the dynamic process of thrombolysis can
n o wb eo b s e r v e do n l i n ea n dt i m e - c o n t i n u o u s l yw i t h o u t
touching the clot and interfering with the process of
lysis. As any model of physiological systems, the method
includes also certain simplifications:
1. The complex function of the endothelium is not con-
s i d e r e da n db l o o dh a st ob er e p l a c e db yas u b s t i t u t et o
avoid uncontrollable coagulation. Interactions between
blood and artificial surfaces of the model will inevitably
lead to unforeseeable changes of coagulation and fibrino-
lysis [32] just like the use of anticoagulated blood [33].
To avoid those complications we decided to use a Ringer
solution as circulating blood substitute and to inject
plasma directly into the clot carrier during the process of
sonothrombolysis. Thereby, we hope to create a physiolo-
gical microenvironment of plasma ensheathing the clot.
Compared with blood, the Ringer solution we used has a
lower viscosity. If the measured effects were attributable
to merely the mechanical properties of the used fluid,
however, they should be more pronounced in vivo.
2. Measurement errors caused by slight changes of the
flow velocity and temperature of the model vary with
the chosen hydrodynamic condition. We calculated an
error adjusted pressure decline for an individual correc-
tion of each modelled hydrodynamic condition. From a
mathematical point of view this is not absolutely correct
because different measurements were offset against each
other.
3. Even the empty clot carrier has a measurable hydro-
dynamic resistance. Therefore the defined normalized
pressure decline that always starts with the value 1 can
never reach value 0. This leads to problems when high
lysis rates of experiments with different flow velocities
are compared, because the final value attained for com-
plete clot dissolution varies in dependence of the
adjusted flow velocity. In such cases the normalized
pressure decline has to be replaced by conversions
based on the measured rating curves (Figure 9).
4. The presented experiments can not differentiate
between mechanical deformation and enzymatic lysis of
the clots. In future the D-dimer level in the streaming
fluid will be determined as a marker for enzymatic fibri-
nolysis to overcome this inaccuracy.
Conclusion
Despite all mentioned limitations, we believe that our
model is suitable for investigating the effects of mechan-
ical and biochemical forces on clot dissolution. Throm-
bolysis is monitored by a new technique that is based
o nt h em e a s u r e m e n to ft h ep r e s s u r ed e c l i n ea tt h ec l o t
carrier. The model enables the assessment of physiologi-
cal flow conditions and non-contact, time-continuous
measurements without disturbing the process of throm-
bolysis, as well as a defined adjustability of parameters
and accessibility for thrombolytics and ultrasound.
The temporal effect of commonly used lysis strate-
gies can now be investigated with high resolution. The
online presentation of the measured data allow for an
interactive and precise change of the model parameter
even during the course of an experiment. Therefore
the model provides ideal conditions for investigations
of the mode of action of sonothrombolysis and will be
a powerful tool in finding the most effective lysis
strategy.
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as conducted for the calibration curves (Figure 7).
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